EUDA
EUDA
EUDA Health Holdings LimitedIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $1.53M | $983.75K | $-602K | -39.38% | $-0.02 | $-519.32K |
| Q1-2025 | $1.53M ▲ | $983.75K ▲ | $-602K ▼ | -39.38% ▼ | $-0.02 ▼ | $-519.32K ▼ |
| Q4-2024 | $1.05M | $655.1K | $735.34K | 69.93% | $-0.01 ▲ | $-476.94K |
| Q3-2024 | $1.05M ▲ | $655.1K ▼ | $735.34K ▲ | 69.93% ▲ | $-0.01 ▲ | $-476.94K ▲ |
| Q2-2024 | $954.02K | $8.39M | $-8.41M | -881.95% | $-0.29 | $-789K |
What's going well?
There are no new negative surprises or worsening losses. The company’s results are stable and predictable, which can help with planning.
What's concerning?
The company is stuck – no revenue growth, high overhead, and ongoing losses. Without improvement, continued losses could threaten long-term survival.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $176.58K | $2.12M | $5.85M | $-3.71M |
| Q1-2025 | $176.58K ▼ | $2.12M ▲ | $5.85M ▲ | $-3.71M ▼ |
| Q4-2024 | $237.6K | $1.7M ▲ | $4.27M ▲ | $-2.55M ▲ |
| Q3-2024 | $237.6K ▼ | $1.7M ▼ | $4.27M ▼ | $-2.55M ▲ |
| Q2-2024 | $376.21K | $2.03M | $8.04M | $-6.02M |
What's financially strong about this company?
Assets are mostly tangible, with little risk of goodwill write-downs. No increase in debt or payables this quarter.
What are the financial risks or weaknesses?
Cash is very low, debts are high and mostly due soon, and equity is deeply negative. The company cannot cover its short-term bills and has a long history of losses.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-602K | $-607.71K | $-11.61K | $558.88K | $0 | $-619.32K |
| Q1-2025 | $-602K ▼ | $-607.71K ▼ | $-11.61K ▲ | $558.88K ▲ | $0 | $-619.32K ▼ |
| Q4-2024 | $735.34K | $-388.06K | $-71.87K | $413.34K | $0 ▲ | $-435.87K |
| Q3-2024 | $735.34K ▲ | $-388.06K ▲ | $-71.87K ▼ | $413.34K ▼ | $-390.58K ▼ | $-435.87K ▲ |
| Q2-2024 | $-8.41M | $-629.3K | $-2.01K | $748.76K | $390.58K | $-629.88K |
What's strong about this company's cash flow?
There are no cash flow strengths this quarter. Capital spending is low, which could limit future cash needs if operations improve.
What are the cash flow concerns?
The company is burning over $600,000 in cash each quarter, has no cash left, and relies entirely on outside funding. Working capital is also draining cash, and there are no shareholder returns.
Revenue by Products
| Product | Q1-2023 |
|---|---|
Medical Service | $0 ▲ |
Property Management Services | $0 ▲ |
5-Year Trend Analysis
A comprehensive look at EUDA Health Holdings Limited's financial evolution and strategic trajectory over the past five years.
EUDA combines a differentiated strategic focus with exposure to attractive end markets. Its integrated AI-driven digital health platform, coupled with wellness products and physical longevity clinics, offers a broader and potentially stickier ecosystem than basic teleconsultation services. The company is targeting high-growth themes such as preventive healthcare, aging populations, and regenerative medicine in Southeast Asia and China. Recently, management has shown some willingness to cut costs, reduce debt, and preserve cash, and the company has demonstrated an ability to raise financing to support its plans.
The primary concerns center on financial sustainability and execution. Revenues have been shrinking, losses and cash burn have been widening, and the balance sheet shows negative equity and weak liquidity, all of which heighten the risk around funding and solvency. The business is reliant on external capital at a time when it is also attempting to pursue complex, capital-intensive initiatives in stem cell therapy and biopharmaceuticals. Competitive pressure from larger, better-funded digital health and wellness players, regulatory and scientific risks in longevity and regenerative medicine, and the cutback in reported R&D spending further compound the uncertainty.
The outlook for EUDA is highly uncertain and will likely be driven by two opposing forces. On one side are powerful structural tailwinds: rising healthcare demand, aging populations, and growing interest in digital health and longevity solutions across Asia. On the other side are very real financial constraints, an unproven ability to scale its ecosystem profitably, and significant regulatory and execution risks. In the near to medium term, the company’s path will likely be dominated by efforts to stabilize its finances, improve cash flow, and demonstrate tangible traction in its longevity and stem cell ventures. Longer term, the ultimate trajectory will depend on whether EUDA can translate its ambitious innovation agenda into sustainable, cash-generating growth before financial pressures limit its strategic options.
About EUDA Health Holdings Limited
https://euda.comEUDA Health Limited develops digital health platform that offers virtual consults for non-emergency medical issues. The company was founded in 2019 and is based in Singapore. EUDA Health Limited company operates as a subsidiary of Watermark Developments Limited.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $1.53M | $983.75K | $-602K | -39.38% | $-0.02 | $-519.32K |
| Q1-2025 | $1.53M ▲ | $983.75K ▲ | $-602K ▼ | -39.38% ▼ | $-0.02 ▼ | $-519.32K ▼ |
| Q4-2024 | $1.05M | $655.1K | $735.34K | 69.93% | $-0.01 ▲ | $-476.94K |
| Q3-2024 | $1.05M ▲ | $655.1K ▼ | $735.34K ▲ | 69.93% ▲ | $-0.01 ▲ | $-476.94K ▲ |
| Q2-2024 | $954.02K | $8.39M | $-8.41M | -881.95% | $-0.29 | $-789K |
What's going well?
There are no new negative surprises or worsening losses. The company’s results are stable and predictable, which can help with planning.
What's concerning?
The company is stuck – no revenue growth, high overhead, and ongoing losses. Without improvement, continued losses could threaten long-term survival.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $176.58K | $2.12M | $5.85M | $-3.71M |
| Q1-2025 | $176.58K ▼ | $2.12M ▲ | $5.85M ▲ | $-3.71M ▼ |
| Q4-2024 | $237.6K | $1.7M ▲ | $4.27M ▲ | $-2.55M ▲ |
| Q3-2024 | $237.6K ▼ | $1.7M ▼ | $4.27M ▼ | $-2.55M ▲ |
| Q2-2024 | $376.21K | $2.03M | $8.04M | $-6.02M |
What's financially strong about this company?
Assets are mostly tangible, with little risk of goodwill write-downs. No increase in debt or payables this quarter.
What are the financial risks or weaknesses?
Cash is very low, debts are high and mostly due soon, and equity is deeply negative. The company cannot cover its short-term bills and has a long history of losses.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-602K | $-607.71K | $-11.61K | $558.88K | $0 | $-619.32K |
| Q1-2025 | $-602K ▼ | $-607.71K ▼ | $-11.61K ▲ | $558.88K ▲ | $0 | $-619.32K ▼ |
| Q4-2024 | $735.34K | $-388.06K | $-71.87K | $413.34K | $0 ▲ | $-435.87K |
| Q3-2024 | $735.34K ▲ | $-388.06K ▲ | $-71.87K ▼ | $413.34K ▼ | $-390.58K ▼ | $-435.87K ▲ |
| Q2-2024 | $-8.41M | $-629.3K | $-2.01K | $748.76K | $390.58K | $-629.88K |
What's strong about this company's cash flow?
There are no cash flow strengths this quarter. Capital spending is low, which could limit future cash needs if operations improve.
What are the cash flow concerns?
The company is burning over $600,000 in cash each quarter, has no cash left, and relies entirely on outside funding. Working capital is also draining cash, and there are no shareholder returns.
Revenue by Products
| Product | Q1-2023 |
|---|---|
Medical Service | $0 ▲ |
Property Management Services | $0 ▲ |
5-Year Trend Analysis
A comprehensive look at EUDA Health Holdings Limited's financial evolution and strategic trajectory over the past five years.
EUDA combines a differentiated strategic focus with exposure to attractive end markets. Its integrated AI-driven digital health platform, coupled with wellness products and physical longevity clinics, offers a broader and potentially stickier ecosystem than basic teleconsultation services. The company is targeting high-growth themes such as preventive healthcare, aging populations, and regenerative medicine in Southeast Asia and China. Recently, management has shown some willingness to cut costs, reduce debt, and preserve cash, and the company has demonstrated an ability to raise financing to support its plans.
The primary concerns center on financial sustainability and execution. Revenues have been shrinking, losses and cash burn have been widening, and the balance sheet shows negative equity and weak liquidity, all of which heighten the risk around funding and solvency. The business is reliant on external capital at a time when it is also attempting to pursue complex, capital-intensive initiatives in stem cell therapy and biopharmaceuticals. Competitive pressure from larger, better-funded digital health and wellness players, regulatory and scientific risks in longevity and regenerative medicine, and the cutback in reported R&D spending further compound the uncertainty.
The outlook for EUDA is highly uncertain and will likely be driven by two opposing forces. On one side are powerful structural tailwinds: rising healthcare demand, aging populations, and growing interest in digital health and longevity solutions across Asia. On the other side are very real financial constraints, an unproven ability to scale its ecosystem profitably, and significant regulatory and execution risks. In the near to medium term, the company’s path will likely be dominated by efforts to stabilize its finances, improve cash flow, and demonstrate tangible traction in its longevity and stem cell ventures. Longer term, the ultimate trajectory will depend on whether EUDA can translate its ambitious innovation agenda into sustainable, cash-generating growth before financial pressures limit its strategic options.

CEO
Alfred Lim
Compensation Summary
(Year )
Upcoming Earnings
Ratings Snapshot
Rating : C

